Evaluation of serum tRF-23-Q99P9P9NDD as a potential biomarker for the clinical diagnosis of gastric cancer

Table 2 Clinicopathological analysis of tRF-23-Q99P9P9NDD

Parameter		No. of patients	tRF-23-Q99P9P9NDD (high)	tRF-23-Q99P9P9NDD (low)	P-value
Sex	Male	83	42	41	0.849
	Female	41	20	21	0.849
Age (year)	< 60	39	18	21	0.562
	≥ 60	85	44	41	0.562
Tumor size	< 5	96	50	46	0.39
	≥ 5	28	12	16	0.39
Differentiation grade	Well-maderate	51	27	24	0.584
	Poor-undifferentiation	73	35	38	0.584
T stage	T1-T2	69	27	42	0.007
	T3-T4	55	35	20	0.007
Lymph node metastasis	Positive	76	47	29	0.001
	Negative	48	15	33	0.001
TNM stage	I–II	82	31	51	< 0.0001
	III–IV	42	31	11	< 0.0001
Nerve/vascular invasion	Positive	78	45	33	0.026
	Negative	46	17	29	0.026
Lauren classification	Intestinal type	34	16	18	0.54
	Mixed type	38	17	21
	Diffuse type	52	29	23
C-erbB-2	Positive	7	3	4	0.697
	Negative	117	59	58	0.697
MMR	dMMR	3	2	1	0.559
	pMMR	121	60	61	0.559

MLH1, PMS2, MSH2, and MSH6 were all positive for pMMR (normal expression), and 1 or more negative for dMMR (deletion)

ISSN: 1528-3658